Month archive: June, 2020

Is it time for a refresh of the Global Financing Facility?

Wemos critically follows the developments and outcomes of the Global Financing Facility (GFF) for Reproductive, Maternal, Newborn, Child and Adolescent Health and Nutrition. It is currently under the process of a ‘strategy refresh’, planned to be launched around September 2020. With our new fact sheet, we looked into the implications of a potential shift from the GFF’s current structure as a Multi-Donor Trust Fund towards a Financial Intermediary Fund.

Continue reading

Social responsibility of the pharmaceutical industry

Pharmaceutical companies have a shared responsibility to ensure equal and unlimited access to health care for the population. Therefore they should provide fairly priced medicines, and should be more transparent about development costs. The current reality, however, is that the costs of intramural medicines are increasing and are bound to become unmanageable. This has a detrimental impact on patients and society. This is the main message of Ella Weggen (Wemos), Wilbert Bannenberg (Pharmaceutical Accountability Foundation) and Robin Veenman (master’s student at the University of Amsterdam) in their article in the edition ‘Een rechtvaardig geneesmiddelbeleid’ (a fair medicines policy) of Podium voor Bio-ethiek.

Continue reading

Upcoming webinar: COVID-19 & the future of pharmaceuticals

Challenges around accessible and affordable medicines have become even more pressing in light of the current COVID-19 pandemic. How can we ensure that publicly funded pharmaceuticals are accessible to patients in Europe and the rest of the world? And what changes do we need to see in EU policy? On Friday June 19th, Members of European Parliament Kim van Sparrentak, Sophie in ‘T Veld, Marc Botenga, together with Commons Network, Fair Medicine, Health Action International, License to Heal, Médecins Sans Frontières, Universities Allied for Essential Medicines NL, and Wemos will discuss these questions (and more) during the online roundtable webinar on ‘Covid-19 and beyond: the future of publicly funded pharmaceuticals to ensure affordable health for all’. Make sure to register!

Continue reading

Invest in health systems strengthening to effectively respond to COVID-19

The COVID-19 pandemic has clearly exposed the cracks in health systems worldwide – but particularly in low-income countries, e.g. in African countries. Our partner organisations in Kenya, Malawi, Mozambique, Tanzania and Uganda shared their concerns about developments on national level, such as the lack of information on COVID-19, health workforce shortages, and disruption of key essential and emergency services including for sexual and reproductive health. We have incorporated these concerns, together with our analysis of COVID-19 and health systems, and our recommendations, in a new joint position paper.

Continue reading